Objective：To investigate the effect of association of Erythropoietin and Midodrine on the cardiac function and hemodynamics in patients with end-stage heart failure. Methods： 43 patients with end-stage heart failure were recruited into this study. Patients were randomly divided into two groups, association treatment group (n=22) and control group (n=21). All patients in the two groups were treated with a standard anti-heart failure therapy and only patients in association treatment group were administrated Erythropoietin, iron and Midodrine. All subjects were followed up for 3 months. The levels of blood pressure, hemoglobin, BNP, LVEF and mean pulmonary artery pressure(mPAP) were examined at the beginning and the end of the study. The rates of cardiovascular events in the two groups were recorded. Results：The levels of blood pressure and hemoglobin were significantly increased and the levels of BNP and the rates of rehospitalization was significantly decreased in the association treatment group (P﹤0.05). There was no significant difference in LVEF and mPAP between the two groups. Conclusion：On the basis of standard therapy, association of Erythropoietin and Midodrine treatment might improve the cardiac function and hemodynamics in patients with end-stage heart failure.
